Opthea Limited
(ASX:OPT) has announced it has received a Notice of Allowance from the United States Patent and Trade Mark Office for its OPT-302 soluable VEGFR-3 ‘trap molecule’, used for the treatment of eye diseases.
The medical developer says it anticipates the patent will be granted in the second half of 2017.
Opthea says the patent will extend to February 2034 and will cover OPT-302 and its uses to treat various eye disorders and diseases, including macular degeneration and diabetic macular edema.
The company says corresponding patent applications are pending in 17 other countries, and has already been granted in South Africa.
Shares in Opthea Limited
(ASX:OPT) opened flat to 78 cents.
